CL2020002290A1 - Compuestos de aminoácidos y métodos de uso. - Google Patents
Compuestos de aminoácidos y métodos de uso.Info
- Publication number
- CL2020002290A1 CL2020002290A1 CL2020002290A CL2020002290A CL2020002290A1 CL 2020002290 A1 CL2020002290 A1 CL 2020002290A1 CL 2020002290 A CL2020002290 A CL 2020002290A CL 2020002290 A CL2020002290 A CL 2020002290A CL 2020002290 A1 CL2020002290 A1 CL 2020002290A1
- Authority
- CL
- Chile
- Prior art keywords
- formula
- methods
- amino acid
- acid compounds
- compounds
- Prior art date
Links
- -1 Amino acid compounds Chemical class 0.000 title 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de la Fórmula (A) y la Fórmula (I):<br /> o una sal de estos, en donde R1, R2, R10, R11, R12, R13, R14, R15, R16, q y p son como se <br /> describen en la presente. Los compuestos de la Fórmula (A) y la Fórmula (I) y las composiciones <br /> farmacéuticas de estos son inhibidores de la integrina αvβ6 que son útiles para tratar la fibrosis, tal como la fibrosis pulmonar idiopática (IPF) y la neumonía intersticial inespecífica (NSIP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639988P | 2018-03-07 | 2018-03-07 | |
| US201862690933P | 2018-06-27 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002290A1 true CL2020002290A1 (es) | 2021-01-15 |
Family
ID=67844341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002290A CL2020002290A1 (es) | 2018-03-07 | 2020-09-04 | Compuestos de aminoácidos y métodos de uso. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10793564B2 (es) |
| EP (2) | EP3761980B1 (es) |
| JP (3) | JP6866535B2 (es) |
| KR (1) | KR20200139676A (es) |
| CN (1) | CN112135612A (es) |
| AU (1) | AU2019230209B2 (es) |
| BR (1) | BR112020018064A2 (es) |
| CA (1) | CA3093225A1 (es) |
| CL (1) | CL2020002290A1 (es) |
| CO (1) | CO2020011085A2 (es) |
| CR (1) | CR20200452A (es) |
| CU (1) | CU24684B1 (es) |
| DK (1) | DK3761980T3 (es) |
| EC (1) | ECSP20063227A (es) |
| FI (1) | FI3761980T3 (es) |
| HR (1) | HRP20240234T1 (es) |
| IL (2) | IL277146B2 (es) |
| JO (1) | JOP20200212A1 (es) |
| LT (1) | LT3761980T (es) |
| MX (2) | MX2020009253A (es) |
| PE (1) | PE20201502A1 (es) |
| PH (1) | PH12020551395A1 (es) |
| PT (1) | PT3761980T (es) |
| RS (1) | RS65170B1 (es) |
| SG (1) | SG11202008609UA (es) |
| TW (1) | TW201938158A (es) |
| WO (1) | WO2019173653A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| KR102605460B1 (ko) | 2017-02-28 | 2023-11-22 | 모픽 테라퓨틱, 인코포레이티드 | αvβ6 인테그린 억제제 |
| BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
| PL3814348T3 (pl) | 2018-06-27 | 2023-09-11 | Bristol-Myers Squibb Company | Podstawione związki naftyrydynonu przydatne jako aktywatory komórek t |
| SG11202013027RA (en) | 2018-06-27 | 2021-01-28 | Pliant Therapeutics Inc | Amino acid compounds with unbranched linkers and methods of use |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| KR102652797B1 (ko) | 2018-10-30 | 2024-04-02 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린의 억제를 위한 화합물 |
| AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| AU2020273158A1 (en) * | 2019-04-08 | 2021-11-11 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ， インコーポレイテッド | α４β７インテグリンの阻害のための化合物 |
| CA3164941A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| US20230181546A1 (en) * | 2020-05-07 | 2023-06-15 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
| CA3173755A1 (en) * | 2020-11-19 | 2022-05-27 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
| KR20240024060A (ko) * | 2021-04-30 | 2024-02-23 | 플라이언트 테라퓨틱스, 인크. | 인테그린 억제제에 대한 확장된 투여량 요법 |
| WO2023225119A1 (en) * | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
| WO2024119067A1 (en) | 2022-12-02 | 2024-06-06 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361764B2 (en) | 1996-12-13 | 2002-03-26 | Societe L'oreal S.A. | Insoluble s-triazine derivatives and their use as UV filters |
| BR9813769A (pt) | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| AU2001269876A1 (en) * | 2000-06-15 | 2001-12-24 | Mark Laurence Boys | Heteroarylalkanoic acids as integrin receptor antagonists |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| MXPA03011046A (es) | 2001-06-01 | 2004-06-25 | Elan Pharm Inc | Hidroxialquilaminas. |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| BR0314180A (pt) | 2002-09-10 | 2005-08-09 | Pharmacia & Upjohn Co Llc | Aminoéteres substituìdos para o tratamento da doença de alzheimer |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| NZ603162A (en) | 2008-06-06 | 2014-05-30 | Boehringer Ingelheim Int | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| US9085606B2 (en) * | 2012-07-18 | 2015-07-21 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファｖベータ１インテグリン阻害剤及び使用方法 |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| WO2017181062A1 (en) | 2016-04-14 | 2017-10-19 | Mars, Incorporated | Compounds that modulate calcium-sensing receptor activity for modulating kokumi taste and pet food products containing the same |
| MX2019000043A (es) * | 2016-07-05 | 2019-07-04 | Univ Rockefeller | Antagonistas de integrina de tetrahidronaftiridinpentanamida. |
| WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| KR102605460B1 (ko) | 2017-02-28 | 2023-11-22 | 모픽 테라퓨틱, 인코포레이티드 | αvβ6 인테그린 억제제 |
| BR112020018064A2 (pt) * | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
| SG11202013027RA (en) | 2018-06-27 | 2021-01-28 | Pliant Therapeutics Inc | Amino acid compounds with unbranched linkers and methods of use |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| AU2020273158A1 (en) | 2019-04-08 | 2021-11-11 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| US20230181546A1 (en) | 2020-05-07 | 2023-06-15 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
-
2019
- 2019-03-07 BR BR112020018064-5A patent/BR112020018064A2/pt unknown
- 2019-03-07 AU AU2019230209A patent/AU2019230209B2/en active Active
- 2019-03-07 MX MX2020009253A patent/MX2020009253A/es unknown
- 2019-03-07 PT PT197651367T patent/PT3761980T/pt unknown
- 2019-03-07 LT LTEPPCT/US2019/021243T patent/LT3761980T/lt unknown
- 2019-03-07 PE PE2020001357A patent/PE20201502A1/es unknown
- 2019-03-07 JP JP2020521559A patent/JP6866535B2/ja active Active
- 2019-03-07 DK DK19765136.7T patent/DK3761980T3/da active
- 2019-03-07 EP EP19765136.7A patent/EP3761980B1/en active Active
- 2019-03-07 CU CU2020000066A patent/CU24684B1/es unknown
- 2019-03-07 EP EP23205993.1A patent/EP4328230A3/en active Pending
- 2019-03-07 SG SG11202008609UA patent/SG11202008609UA/en unknown
- 2019-03-07 CN CN201980030750.4A patent/CN112135612A/zh active Pending
- 2019-03-07 CR CR20200452A patent/CR20200452A/es unknown
- 2019-03-07 IL IL277146A patent/IL277146B2/en unknown
- 2019-03-07 KR KR1020207026985A patent/KR20200139676A/ko not_active Application Discontinuation
- 2019-03-07 TW TW108107688A patent/TW201938158A/zh unknown
- 2019-03-07 HR HRP20240234TT patent/HRP20240234T1/hr unknown
- 2019-03-07 RS RS20240183A patent/RS65170B1/sr unknown
- 2019-03-07 FI FIEP19765136.7T patent/FI3761980T3/fi active
- 2019-03-07 CA CA3093225A patent/CA3093225A1/en active Pending
- 2019-03-07 JO JOP/2020/0212A patent/JOP20200212A1/ar unknown
- 2019-03-07 IL IL305296A patent/IL305296A/en unknown
- 2019-03-07 US US16/296,194 patent/US10793564B2/en active Active
- 2019-03-07 WO PCT/US2019/021243 patent/WO2019173653A1/en active Application Filing
-
2020
- 2020-06-26 US US16/914,209 patent/US11560376B2/en active Active
- 2020-09-04 CL CL2020002290A patent/CL2020002290A1/es unknown
- 2020-09-04 MX MX2022014456A patent/MX2022014456A/es unknown
- 2020-09-07 PH PH12020551395A patent/PH12020551395A1/en unknown
- 2020-09-07 CO CONC2020/0011085A patent/CO2020011085A2/es unknown
- 2020-10-06 EC ECSENADI202063227A patent/ECSP20063227A/es unknown
-
2021
- 2021-04-07 JP JP2021065309A patent/JP7273882B2/ja active Active
-
2022
- 2022-12-19 US US18/084,307 patent/US20230271960A1/en active Pending
-
2023
- 2023-04-28 JP JP2023074346A patent/JP2023106425A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002290A1 (es) | Compuestos de aminoácidos y métodos de uso. | |
| CU20210001A7 (es) | Compuestos de aminoácido con ligadores no ramificados como inhibidores de la integrina y composiciones farmacéuticas que los comprenden | |
| ECSP21032717A (es) | Compuestos de aminoácidos y métodos de uso | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| PE20141607A1 (es) | Compuestos heterociclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparacion | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| EA202090119A1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA201491276A1 (ru) | Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 | |
| NI201500139A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
| CL2020002550A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. | |
| AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 | |
| EA201491442A1 (ru) | Твердые формы, содержащие ингибиторы ns5a вируса гепатита с, их композиции и их применение | |
| CO2023016295A2 (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
| CR20110082A (es) | Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| TH129186A (th) | สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors) |